Biotest AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
February 02, 2018 at 09:50 am
Share
DGAP Voting Rights Announcement: Biotest AG
Biotest AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
02.02.2018 / 10:44
Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Notification of Major Holdings
1. Details of issuer
Biotest AG
Landsteinerstraße 5
63303 Dreieich
Germany
2. Reason for notification
X
Acquisition/disposal of shares with voting rights
Acquisition/disposal of instruments
Change of breakdown of voting rights
Other reason:
3. Details of person subject to the notification obligation
Name:
City and country of registered office:
Mr Yuewen Zheng, Date of birth: 11 Jan 1962
4. Names of shareholder(s)
holding directly 3% or more voting rights, if different from 3.
Tiancheng (Germany) Pharmaceutical Holdings AG
5. Date on which threshold was crossed or reached:
31 Jan 2018
6. Total positions
% of voting rights attached to shares (total of 7.a.)
% of voting rights through instruments (total of 7.b.1 + 7.b.2)
total of both in % (7.a. + 7.b.)
total number of voting rights of issuer
Resulting situation
89.88 %
0 %
89.88 %
19785726
Previous notification
0 %
0 %
0 %
/
7. Notified details of the resulting situation a. Voting rights attached to shares (Sec.s 33, 34 WpHG)
ISIN
absolute
in %
direct (Sec. 33 WpHG)
indirect (Sec. 34 WpHG)
direct (Sec. 33 WpHG)
indirect (Sec. 34 WpHG)
DE0005227201
17783776
%
89.88 %
Total
17783776
89.88 %
b.1. Instruments according to Sec. 38 para. 1 No. 1 WpHG
Type of instrument
Expiration or maturity date
Exercise or conversion period
Voting rights absolute
Voting rights in %
%
Total
%
b.2. Instruments according to Sec. 38 para. 1 No. 2 WpHG
Type of instrument
Expiration or maturity date
Exercise or conversion period
Cash or physical settlement
Voting rights absolute
Voting rights in %
%
Total
%
8. Information in relation to the person subject to the notification obligation
Person subject to the notification obligation is not controlled and does itself not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer (1.).
X
Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity:
Name
% of voting rights (if at least held 3% or more)
% of voting rights through instruments (if at least held 5% or more)
Total of both (if at least held 5% or more)
Yuewen Zheng
%
%
%
Creat Group Co., Ltd.
%
%
%
Creat Tiancheng Investment Holdings Co., Ltd.
%
%
%
Tiancheng Fortune Management Limited
%
%
%
Tiancheng International Investment Limited
%
%
%
Tiancheng (Germany) Pharmaceutical Holdings AG
89.88 %
%
89.88 %
9. In case of proxy voting according to Sec. 34 para. 3 WpHG
Date of general meeting:
Holding position after general meeting:
% (equals voting rights)
10. Other explanatory remarks:
02.02.2018 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
Biotest AG is a Germany-based provider of plasma proteins and biological drugs. The Company, with a chain that extends from pre-clinical and clinical development to worldwide marketing and distribution, mainly specializes in the areas of clinical immunology, hematology, and intensive care medicine. It develops, manufactures, and markets immunoglobulin, coagulation factors, and albumins based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. In addition, the Company develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus, which are produced by recombinant technologies.